Novo Nordisk's stock rises as Ozempic beat analysts' expectations in sales

Novo Nordisk's stock rebounded from a three-day decline on Wednesday, as the drug maker reported a Q4 beat, driven by strong sales of Ozempic.

In the December quarter, sales of Ozempic rose 7 per cent to reach $4.71 billion. This number surpassed the $4.59-billion forecast from analysts, as reported by FactSet.

Wegovy misses sales forecast

Meanwhile, Novo Nordisk's Wegovy generated $2.77 billion in sales. Although this represented a year-on-year (YoY) increase of over 97 per cent, it fell short of the sales estimate of $2.78 billion.


While Ozempic is meant for the treatment of diabetes, Wegovy is marketed as a weight-management drug, with both using semaglutide as their active ingredient.

Also Read : Milwaukee Bucks trade Khris Middleton for Kyle Kuzma in major deal with Washington Wizards

Novo stock rises

Novo Nordisk's stock rose by more than 4 per cent in morning trading on Wednesday, as reported by Investor's Business Daily. In its outlook for the current year, the pharmaceutical giant has forecast continued periodic supply constraints and related drug shortage notifications.

Novo estimates slower growth for 2025

Novo Nordisk has reportedly projected slower growth for 2025. According to Reuters, the Danish pharmaceutical manufacturer expects sales growth between 16 per cent and 24 per cent, following a 26 per cent growth in 2024.

Also Read : Gemini 2.0 opens for everyone, Google announces

FAQs

1. What’s the difference between Ozempic and Wegovy?
Though Ozempic and Wegovy both contain semaglutide as their active ingredient, they are marketed for different purposes. Ozempic is approved for the treatment of diabetes, while Wegovy is prescribed for weight management. The dosage of semaglutide also differs between the two drugs.

2. How has Novo Nordisk forecast its growth for this year?
Novo Nordisk has projected a slower sales growth for the current year compared to 2024. The company expects a growth rate between 16 per cent and 24 per cent, following a 26 per cent growth last year.